BioSpace News Archive

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences:

Zynex, Inc., an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced reaching four hundred sales reps in the U.S.

Company’s ultra-sensitive platform continues to facilitate important advances that harness biomarkers to identify, monitor and validate treatment pathways for Multiple Sclerosis (MS) BILLERICA, Mass.--( BUSINESS WIRE )-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa® technology has been used by leading research teams to power

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced data from an observational study demonstrating that younger donor age is associated with more rapid time to neutrophil engraftment and increased overall survival in patients who received hematopoietic stem cell transplant (HSCT, or bone marrow transplant) for the treatment of hematological malignancies.

TFF Pharmaceuticals to Present at the H.C. Wainwright 22 nd Annual Global Investment Conference Corporate presentation and live webcast scheduled for Monday, September 14, 2020 at 4:00 PM EDT AUSTIN, Texas--( BUSINESS WIRE )-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has be

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer and Andy Yates, PhD, Interim Chief Scientific Officer, will participate in separate keynote panels at the 3rd Annual International Cannabinoid Derived Pharmaceuticals Summit, being held virtually on September 15-17, 2020.

Human milk is known for its protective benefits, especially for preterm and immunocompromised infants who are at higher risk for necrotizing enterocolitis (NEC), sepsis, and mortality.

LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is collaborating with Diopsys, a leading provider of modern visual electrophysiology solutions

Recently completed tests in the United States at the Colorado State University Biological Safety Level 3 (BSL-3) research laboratory have demonstrated, for the first time, that the surface material of a new face mask can eliminate more than 99.99 percent of the SARS-CoV-2 virus strain within 30 minutes.